DIVISLAB2019-07-012019-09-30in-bse-fin:OneOperatingExpenses01Member DIVISLAB2019-07-012019-09-30in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares DIVISLAB 2019-04-01 2020-03-31 2019-10-25 INR Lakhs Half yearly Single segment Pharmaceuticals 2019-07-01 2019-09-30 Unaudited Standalone 14039200000.00 473600000.00 14512800000.00 6069900000.00 0.00 -295600000.00 1475800000.00 37900000.00 459100000.00 1935500000.00 9682600000.00 4830200000.00 0.00 4830200000.00 1195100000.00 106800000.00 1301900000.00 0.00 3528300000.00 0.00 0.00 0.00 0.00 3528300000.00 2600000.00 3530900000.00 0.00 0.00 530900000.00 2 13.29 13.29 0.00 0.00 13.29 13.29 1. The above Statement of standalone unaudited financial results for the quarter and half year ended 30th September, 2019, Statement of standalone unaudited assets and liabilities as at 30th September, 2019 and Statement of standalone unaudited cash flows for the half year ended 30th September, 2019 (‘Standalone Statements’) are prepared in accordance with Indian Accounting Standards (‘Ind AS’) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The same were, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 5th November, 2019. The same also were subjected to ‘limited review’ by the Auditors of the Company and their report contains no qualification. n2. The comparative figures of cash flows for the half year ended 30th September, 2018 included in the above referred Standalone Statements were as reviewed by the Audit Committee and approved by the Board of Directors only and have not been subjected to review by the Auditors as the mandatory requirement of limited review of cash flows has been made applicable for the period beginning from 1st April 2019 pursuant to Regulation 33(8) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. n3. The Company is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates and nutraceutical ingredients; and the same constitutes a single reportable business segment as per Ind AS 108. n4. The Company does not have any discontinued operations and the Profit for the period represents the Profits from continuing operations only. n5. As approved by the Members of the Company at the 29th Annual General Meeting held on 23rd August, 2019, a dividend of Rs. 16/- per equity share of Rs.2/- each for the year ended 31st March, 2019, aggregating to Rs 42475 lakhs, has been paid on 27th August, 2019. n6. The Ministry of Corporate Affairs (MCA), on 30th March, 2019, notified Ind AS 116 Leases as part of the Companies (Indian Accounting Standard) Amendment Rules, 2019. The new Standard is effective for accounting periods beginning on or after 1st April, 2019. The adoption of the Standard did not have any material impact to the financial results of the Company. n7. Details of forex gain/(loss) are as given below: n (Rs. in Lakhs) nt Quarter endedt Half Year endedt Year ended nt 30.09.2019t30.06.2019 30.09.2018t30.09.2019 30.09.2018t31.03.2019 nForex gain/(loss)t1294t (596)t 5278t 698t 7947t3092 n Forex gain has been included in Other Income and loss has been included in Other Expenses. n8. Figures for the previous year/period have been reclassified/ regrouped wherever necessary to conform to current year’s classification. 2019-04-01 2019-09-30 Unaudited Standalone 25438400000.00 730300000.00 26168700000.00 11109700000.00 0.00 -798100000.00 2855300000.00 41100000.00 897200000.00 3572200000.00 17677400000.00 8491300000.00 0.00 8491300000.00 2131600000.00 157900000.00 2289500000.00 0.00 6201800000.00 0.00 0.00 0.00 0.00 6201800000.00 5600000.00 6207400000.00 0.00 0.00 530900000.00 2 23.36 23.36 0.00 0.00 23.36 23.36 Other Expenses 1935500000.00 Other Expenses 3572200000.00